Abstracts tagged "Activity score and systemic lupus erythematosus (SLE)"

Abstract Number: 610 • 2012 ACR/ARHP Annual Meeting
B Lymphocyte Stimulator Levels Are Higher in Caucasian SLE Patients Earlier in Disease Course and Predict Damage Accumulation
Eoghan M. McCarthy¹, Ruth Lee¹, Joan Ni Gabhann², Siobhan Smith², Michele Doran³, Gaye Cunnane³, Donough G. Howard¹, Paul G. O'Connell⁴, Grainne M. Kearns⁵ and Caroline Jefferies², ¹Rheumatology, Beaumont Hospital, Dublin 9, Ireland, ²Molecular and Cellular Therapeutics, Royal College of Surgeons in Ireland, Dublin, Ireland, ³Dept of Rheumatology, St. James Hospital, Dublin, Ireland, ⁴Department of Rheumatology, Beaumont Hospital, Dublin 9, Ireland, ⁵Rheumatology Department, Beaumont Hospital, Dublin, Ireland
Background/Purpose: B Lymphocyte Stimulator(BLyS) plays an important role in the pathogenesis of Systemic Lupus Erythematosus(SLE). Whilst trials of anti BLyS-targeted therapy have shown promise, the optimal…
Abstract Number: 941 • 2012 ACR/ARHP Annual Meeting
Validity and Reliability of the Systemic Lupus Activity Questionnaire (SLAQ): A Prospective Study
Yuko Okamoto, Yasuhiro Katsumata, Yasushi Kawaguchi, Sayumi Baba, Kae Takagi, Hisae Ichida, Takahisa Gono, Masanori Hanaoka, Yuko Ota and Hisashi Yamanaka, Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan
Background/Purpose: Traditional assessments of systemic lupus erythematosus (SLE) disease activity, such as the SLE Disease Activity Index 2000 (SLEDAI-2K) and the Systemic Lupus Activity Measure…

All abstracts accepted to ACR Convergence are under embargo once the ACR has notified presenters of their abstract’s acceptance, and cannot be presented at other meetings after this time. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until November 7 at 10:00 AM ET. Journalists with access to embargoed information also cannot release articles before this time.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Permissions and Reprints

For information about abstract permissions and reprints, see ACR Convergence permissions and reprint policies.